BioLeap

Overview:

BioLeap is an emerging drug design services and technology company serving the pharmaceutical and biotech markets. Enabled by next generation computational fragment-based design methodologies, the Company's simulation and tools suite lets medicinal chemists identify and optimize lead compounds where other approaches have not been successful. BioLeap's process creates novel compounds with intellectual property protection, enhances the intellectual property estate around existing compounds, avoids obstructive patents and generates fast-follower compounds for early market entry.
www.bioleap.com

Recent BioLeap News